脉冲电场消融治疗转移性乳腺癌
影像引导脉冲电场(PEF)消融转移性乳腺癌软组织病灶:一项试点研究
This is a phase I trial of the safety of image-guided pulsed electric field (PEF) ablation for the locoregional treatment of superficial soft tissue lesions in adults with metastatic breast cancer using the AliyaTM Pulsed Electric Field System.
研究概览
地位
详细说明
PRIMARY OBJECTIVE:
I. To assess the safety of PEF for locoregional treatment of soft tissue metastatic breast cancer lesions.
SECONDARY OBJECTIVE:
I. To assess the effect of PEF on patient-reported symptoms and quality of life.
II. To assess the feasibility of performing PEF for superficial soft tissue metastases.
EXPLORATORY OBJECTIVE:
I. To explore blood-based biomarker responses to PEF.
II. To explore the efficacy of PEF in treating locoregional disease, as well as its effect on untreated lesions.
OUTLINE:
Participants will receive a single treatment of PEF ablation delivered to up to 3 soft metastatic breast cancer lesion(s). After the treatment, participants are followed at Day 0, week 2, week 4, and up to 1 year post ablation.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Maya Aslam
- 电话号码:877-827-3222
- 邮箱:maya.aslam@ucsf.edu
学习地点
-
-
California
-
San Francisco、California、美国、94143
- 招聘中
- University of California San Francisco
-
首席研究员:
- Ryan Kohlbrenner, MD
-
接触:
-
接触:
- Maya Aslam
- 电话号码:877-827-3222
- 邮箱:Maya.Aslam@ucsf.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Participants must have histologically or cytologically confirmed metastatic breast cancer.
-
Confirmed documented soft tissue involvement via imaging or biopsy, with at least one measurable lesion with a cutaneous and/or subcutaneous component that is at least 1 cm in size but no greater than 5 cm in size and that can be safely accessed under image guidance. Up to 3 lesions that meet these criteria may be treated with PEF ablation therapy.
-
There are no limits on the amount of prior or concurrent anti-cancer therapies, but patients must be medically able (in the opinion of referring provider and treating investigator) to withhold their systemic therapy for breast cancer one week before the PEF ablation and for 2 weeks after the procedure.
-
Age ≥18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
-
Adequate Bone Marrow Function:
- Absolute neutrophil count ≥1,500/microliter (mcL).
- Platelets ≥100,000/mcL.
-
Not on or able to withhold anticoagulation or antiplatelet therapy per Society of Interventional Radiology periprocedural guideline.
-
Human immunodeficiency virus (HIV)-infected individuals on effective anti-retroviral therapy with undetectable viral load within 6 months (as documented in the medical record) are eligible for this trial.
-
For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy (as documented in the medical record), if indicated.
-
Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load (as documented in the medical record).
-
Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
The effects of pulsed electric field on the developing human fetus are unknown. For this reason individuals of reproductive potential must agree to use adequate contraception: (e.g., hormonal or barrier method of birth control; abstinence, etc.) for the duration of study participation and for 4 weeks after last administration of study treatment. Should a study participant become pregnant or suspect pregnancy while participating in this study, they should inform their treating physician immediately.
Exclusion Criteria:
- Has not recovered from adverse events due to prior/concurrent systemic anti-cancer therapy to ≤ Grade 2 (CTCAE v5.0) or baseline (other than alopecia).
- Individuals with pacemakers or other electronic implant devices.
- Individuals who are unable or unwilling, or with medical contraindication, to undergo moderate sedation and local anesthesia.
- Pregnant individuals are excluded from this study because there is unknown risk of PEF on fetus.
- Breastfeeding/chestfeeding individuals are excluded from this study because there is unknown risk on nursing infants; breastfeeding/chestfeeding should be discontinued prior to initiating study treatment.
- Individuals with any condition or social circumstance that, in the opinion of the treating investigator, would impair the participant's ability to comply with study procedures.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Image-Guided Pulsed Electric Field (PEF) Ablation
Participants undergo a single treatment of PEF ablation delivered to up to 3 soft tissue metastatic breast cancer lesion(s). Ablation parameters, immediate adverse events, and post-ablation imaging will be collected during the ablation treatment. |
Pulsed electric field (PEF) delivers short, high frequency electrical pulses that are intended to shrink or destroy tumors
其他名称:
Participants will complete health related, quality of life questionnaires Undergo ablation via PEF
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of participants with treatment-emergent adverse events
大体时间:Up to 4 weeks
|
Proportion of participants who experience adverse event from the Pulsed Electric Field (PEF) ablation treatment. Standard deviation and 95% confidence intervals will be reported. |
Up to 4 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mean change of score on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Breast Cancer Module (EORTC QLQ BR-23)
大体时间:Up to 4 weeks
|
EORTC QLQ-BR23 incorporates five multi-item scales to assess body image, sexual functioning, systemic therapy side effects, breast symptoms, and arm symptoms. In addition, single items assess sexual enjoyment, future perspective and being upset by hair loss. All of the scales and single-item measures range in score from 0 to 100. The mean and standard deviation of the change in EORTC QLQ-BR23 scores, along with the 95% confidence interval, will be reported. |
Up to 4 weeks
|
|
Mean change of score on EuroQol five-dimensional Questionnaire (EQ-5D)
大体时间:Up to 4 weeks
|
EQ-5D is a standardized instrument for measuring generic health status. The health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The respondents self-rate their level of severity for each dimension by selecting one of the following responses: no problems (0), slight problems (1), mild problems (2), moderate problems (3), or severe problems (4) with a particular dimension. The mean and standard deviation of the change in EQ-5D scores, along with the 95% confidence interval, will be reported. |
Up to 4 weeks
|
|
Mean technical success rate of Pulsed Electric Field (PEF) ablation
大体时间:Up to 1 day
|
Immediately after PEF ablation, the technical success rate and any procedural technical challenges will be recorded. Mean, standard deviation of technical success rate for PEF ablation and 95% confidence will be reported. |
Up to 1 day
|
合作者和调查者
调查人员
- 首席研究员:Ryan Kohlbrenner, MD、University of California, San Francisco
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 259216
- NCI-2026-01819 (注册表标识符:NCI Clinical Trials Reporting System (CTRP))
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.